Clinical Trial Update: BIBF 1120 in Bevacizumab Resistant, Persistent, or Recurrent Epithelial Ovarian Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for BIBF 1120 in bevacizumab-resistant, persistent, or recurrent epithelial ovarian cancer has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fallopian Tube Cancer
• Ovarian Cancer
• Peritoneal Cancer

Drugs mentioned

• BIBF 1120 (nintedanib)

Snippet

Sponsor: AA Secord | Conditions: Ovarian Cancer, Fallopian Tube Cancer | Phase 2 | Status: COMPLETED | Results posted: 2018-10-16